CytoSorbents Corporation

7.61-0.0100-0.13%Vol 147.57K1Y Perf -20.88%
Jul 30th, 2021 16:00 DELAYED
BID7.61 ASK7.64
Open7.70 Previous Close7.62
Pre-Market- After-Market7.61
 - -  - -%
Target Price
14.88 
Analyst Rating
Strong Buy 1.00
Potential %
95.53 
Finscreener Ranking
★★★★     54.70
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★+     48.82
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★★★     60.84
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Market Cap329.66M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
10.55 
Earnings Date
3rd Aug 2021

Today's Price Range

7.587.75

52W Range

7.1311.68

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
2.01%
1 Month
0.79%
3 Months
-17.73%
6 Months
-27.45%
1 Year
-20.88%
3 Years
-36.58%
5 Years
55.31%
10 Years
-

TickerPriceChg.Chg.%
CTSO7.61-0.0100-0.13
AAPL145.860.22000.15
GOOG2 704.42-26.3900-0.97
MSFT284.91-1.5900-0.55
XOM57.57-1.3600-2.31
WFC45.94-0.5600-1.20
JNJ172.200.02000.01
FB356.30-2.0200-0.56
GE12.95-0.3400-2.56
JPM151.78-1.2200-0.80
Financial StrengthValueIndustryS&P 500US Markets
7.50
8.20
0.01
0.01
-9.70
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
72.40
-20.50
-19.00
-74.30
-16.62
RevenueValueIndustryS&P 500US Markets
33.10M
0.77
23.31
37.73
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.03-0.10-233.33
Q04 2020-0.020.00100.00
Q03 2020-0.09-0.0277.78
Q02 2020-0.08-0.080.00
Q01 2020-0.14-0.1028.57
Q04 2019-0.17-0.1323.53
Q03 2019-0.14-0.21-50.00
Q02 2019-0.14-0.1121.43
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.030.00-
9/2021 QR-0.030.00-
12/2021 FY-0.18-50.00Negative
12/2022 FY0.090.00-
Next Report Date3rd Aug 2021
Estimated EPS Next Report-0.03
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume147.57K
Shares Outstanding43.32M
Trades Count1.50K
Dollar Volume2.99M
Avg. Volume289.71K
Avg. Weekly Volume129.77K
Avg. Monthly Volume290.41K
Avg. Quarterly Volume241.01K

CytoSorbents Corporation (NASDAQ: CTSO) stock closed at 7.61 per share at the end of the most recent trading day (a -0.13% change compared to the prior day closing price) with a volume of 147.57K shares and market capitalization of 329.66M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 156 people. CytoSorbents Corporation CEO is Phillip P. Chan.

The one-year performance of CytoSorbents Corporation stock is -20.88%, while year-to-date (YTD) performance is -4.52%. CTSO stock has a five-year performance of 55.31%. Its 52-week range is between 7.13 and 11.68, which gives CTSO stock a 52-week price range ratio of 10.55%

CytoSorbents Corporation currently has a PE ratio of -, a price-to-book (PB) ratio of 63.48, a price-to-sale (PS) ratio of 9.65, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -12.71%, a ROC of -13.42% and a ROE of -17.12%. The company’s profit margin is -16.62%, its EBITDA margin is -19.00%, and its revenue ttm is $33.10 Million , which makes it $0.77 revenue per share.

Of the last four earnings reports from CytoSorbents Corporation, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.03 for the next earnings report. CytoSorbents Corporation’s next earnings report date is 03rd Aug 2021.

The consensus rating of Wall Street analysts for CytoSorbents Corporation is Strong Buy (1), with a target price of $14.88, which is +95.53% compared to the current price. The earnings rating for CytoSorbents Corporation stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CytoSorbents Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CytoSorbents Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 24.66, ATR14 : 0.33, CCI20 : -27.17, Chaikin Money Flow : 0.27, MACD : -0.10, Money Flow Index : 49.84, ROC : -1.42, RSI : 46.74, STOCH (14,3) : 54.02, STOCH RSI : 0.93, UO : 45.04, Williams %R : -45.98), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CytoSorbents Corporation in the last 12-months were: Al W. Kraus (Option Excercise at a value of $27 600), Al W. Kraus (Sold 8 000 shares of value $64 000 ), Edward R. Jones (Option Excercise at a value of $26 800), Kathleen P. Bloch (Option Excercise at a value of $56 000)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
4 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

CytoSorbents Corporation

CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries.The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend, K ontrol, and DrugSorb. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending.

CEO: Phillip P. Chan

Telephone: +1 732 329-8885

Address: 7 Deer Park Drive, Monmouth Junction 08852, NJ, US

Number of employees: 156

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

54%46%

Bearish Bullish

56%44%

News

Stocktwits